BR112012021401A2 - método para normalizar rapidamente níveis de vitamina b12, método para normalizar vitamina b12 ativa, método para reduzir níveis de ácido metil malônico, método para reduzir níveis de homocisteína, método para reduzir a variabilidade entre sujeitos no tratamento oral de pacientes sofrendo de deficiência de vitamina b12 e forma de dosagem oral - Google Patents

método para normalizar rapidamente níveis de vitamina b12, método para normalizar vitamina b12 ativa, método para reduzir níveis de ácido metil malônico, método para reduzir níveis de homocisteína, método para reduzir a variabilidade entre sujeitos no tratamento oral de pacientes sofrendo de deficiência de vitamina b12 e forma de dosagem oral

Info

Publication number
BR112012021401A2
BR112012021401A2 BR112012021401A BR112012021401A BR112012021401A2 BR 112012021401 A2 BR112012021401 A2 BR 112012021401A2 BR 112012021401 A BR112012021401 A BR 112012021401A BR 112012021401 A BR112012021401 A BR 112012021401A BR 112012021401 A2 BR112012021401 A2 BR 112012021401A2
Authority
BR
Brazil
Prior art keywords
vitamin
reducing
levels
normalizing
subjects
Prior art date
Application number
BR112012021401A
Other languages
English (en)
Other versions
BR112012021401B1 (pt
Inventor
Cristina Castelli
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BR112012021401A2 publication Critical patent/BR112012021401A2/pt
Publication of BR112012021401B1 publication Critical patent/BR112012021401B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
BR112012021401A 2010-02-24 2011-02-23 forma de dosagem oral BR112012021401B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30783610P 2010-02-24 2010-02-24
PCT/US2011/025864 WO2011106378A2 (en) 2010-02-24 2011-02-23 Oral b12 therapy

Publications (2)

Publication Number Publication Date
BR112012021401A2 true BR112012021401A2 (pt) 2016-10-25
BR112012021401B1 BR112012021401B1 (pt) 2019-12-24

Family

ID=44477007

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012021401A BR112012021401B1 (pt) 2010-02-24 2011-02-23 forma de dosagem oral

Country Status (16)

Country Link
US (3) US20110207693A1 (pt)
EP (2) EP3028709B1 (pt)
JP (3) JP2013520511A (pt)
KR (1) KR20130026429A (pt)
AR (1) AR080292A1 (pt)
AU (1) AU2011220867B2 (pt)
BR (1) BR112012021401B1 (pt)
CA (2) CA2790708A1 (pt)
CL (1) CL2012002358A1 (pt)
CO (1) CO6602160A2 (pt)
HK (1) HK1225609A1 (pt)
MX (1) MX2012009914A (pt)
NZ (2) NZ701274A (pt)
RU (1) RU2576511C2 (pt)
TW (1) TWI590829B (pt)
WO (1) WO2011106378A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066375A1 (en) 2011-11-05 2013-05-10 South Alabama Medical Science Foundation Methods, formulations, and kits for rapidly repleting folate levels in women
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6274564B1 (en) * 1996-09-18 2001-08-14 William J. Sarill Compositions of cobalamin and related corrinoids, and uses thereof
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
ES2386263T3 (es) * 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JP2004526793A (ja) * 2001-04-25 2004-09-02 コバルツ リミテッド 個体における機能性ビタミンｂ１２欠乏症を治療または予防するための方法、およびこの方法に使用するための医療用組成物
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AU2003275329B2 (en) * 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
DE10311089A1 (de) * 2003-03-13 2004-09-23 Roche Diagnostics Gmbh Differenzialdiagnostik und Monitoring von Vitamin B12-, Vitamin B6- und Folsäure-Störungen mittels vier unabhängiger Messgrößen
MXPA06000446A (es) * 2003-07-11 2006-04-07 Novartis Ag Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada.
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
EP1773351B1 (en) * 2004-05-06 2019-04-24 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
MX2007001348A (es) * 2004-08-02 2008-03-11 Bebaas Inc Composiciones de vitamina b12.
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
DK1797127T3 (en) * 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
AU2006312117A1 (en) * 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods
BRPI0601834A (pt) * 2006-03-30 2007-11-27 Ricardo De Souza Pereira suplementação dietética para curar ou regredir sintomas de refluxo gastroesofágico, gastrite e úlceras
DE102007005952A1 (de) * 2007-02-06 2008-08-07 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit an einer Schiene aufgehängten Fachböden
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
ES2443817T3 (es) * 2007-11-02 2014-02-20 Emisphere Technologies, Inc. Método para tratar la deficiencia de vitamina B12

Also Published As

Publication number Publication date
TWI590829B (zh) 2017-07-11
US20110207693A1 (en) 2011-08-25
CL2012002358A1 (es) 2012-12-14
JP2015193660A (ja) 2015-11-05
EP3028709A1 (en) 2016-06-08
AU2011220867B2 (en) 2014-05-15
MX2012009914A (es) 2013-03-05
RU2012136176A (ru) 2014-03-27
KR20130026429A (ko) 2013-03-13
JP2013520511A (ja) 2013-06-06
JP2017101081A (ja) 2017-06-08
RU2576511C2 (ru) 2016-03-10
WO2011106378A3 (en) 2011-11-24
EP3028709B1 (en) 2019-08-28
CO6602160A2 (es) 2013-01-18
BR112012021401B1 (pt) 2019-12-24
US20200206247A1 (en) 2020-07-02
TW201200139A (en) 2012-01-01
AU2011220867A1 (en) 2012-09-20
CA2996757A1 (en) 2011-09-01
HK1225609A1 (zh) 2017-09-15
US20160074420A1 (en) 2016-03-17
EP2538945A2 (en) 2013-01-02
NZ602032A (en) 2014-11-28
EP2538945A4 (en) 2013-07-24
NZ701274A (en) 2016-03-31
WO2011106378A2 (en) 2011-09-01
CA2790708A1 (en) 2011-09-01
AR080292A1 (es) 2012-03-28

Similar Documents

Publication Publication Date Title
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
PL2908798T3 (pl) Pasek do wprowadzania środka aktywującego higienę jamy ustnej i sposoby stosowania środków aktywujących higienę jamy ustnej
CO6880067A2 (es) Inhibidores de corrientes \"funny\" (if) para utilizar en un método de tratamiento y prevención de la insuficiencia cardíaca en felinos
BR112015000441A2 (pt) imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
IL220040A0 (en) Methods and low dose regimens for treating red blood cell disorders
EP2691149A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF APNEA WITH EXCLUSIVE SWALLOWS
BR112014002718A2 (pt) célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
BR112013013469A2 (pt) cápsula farmacêutica oral, método para tratar hiperfosfatemia em um paciente, método para tratar um paciente e pó farmacêutico oral
EA201370008A1 (ru) Лечение когнитивных нарушений
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
ZA201205441B (en) Dental strip for administration of oral treatment
HK1207593A1 (en) Medicament for treating mental and behavioural disorders
ZA201502288B (en) Ciclesonide for treatment of airway disease in horses
BR112015005335A8 (pt) composição farmacêutica para tratar uma ferida, método para tratar uma ferida, composição farmacêutica contida em uma embalagem e kit para tratar uma ferida em um sujeito
BR112012021401A2 (pt) método para normalizar rapidamente níveis de vitamina b12, método para normalizar vitamina b12 ativa, método para reduzir níveis de ácido metil malônico, método para reduzir níveis de homocisteína, método para reduzir a variabilidade entre sujeitos no tratamento oral de pacientes sofrendo de deficiência de vitamina b12 e forma de dosagem oral
EP2726079A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
BR112013019775A2 (pt) composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.